News | June 01, 2021
Jubilant to invest US $92 mn to expand sterile injectable capacity
This investment is being made to set up a high speed 400 vials a minute injectable fill line with isolator technology
This investment is being made to set up a high speed 400 vials a minute injectable fill line with isolator technology
India formulations business grew 14.7% YoY with recovery in industry growth from COVID-19 impact
The company reported total income of Rs.24774.63 crores during the 12 months period ended March 31, 2021
7.94 crore doses were made available to the states in May 2021
US revenues were sequentially stable at US$370mn with steady performance in the specialty portfolio
Cadila's ZyCov-D (DNA-based vaccine) is undergoing phase III trials.
The company has posted net profit of Rs.1140.01 crores during FY 2020-21
The patients can check to see if the product purchased by them is genuine or not by scratching the surface and verifying the code through the app or the website
It posted net profit of Rs.60.96 crores for the 12 months period ended March 31, 2021
For the year ended March 31, 2021, consolidated revenue was at Rs. 10,943.9 crores as against Rs. 10,641 crores, recording an increase of 2.8% over the previous corresponding period
Subscribe To Our Newsletter & Stay Updated
